{"id":3651540,"date":"2024-06-26T19:45:00","date_gmt":"2024-06-26T23:15:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer\/"},"modified":"2025-12-31T12:58:07","modified_gmt":"2025-12-31T17:58:07","slug":"patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer\/","title":{"rendered":"Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer"},"content":{"rendered":"<p><strong>The letter did not identify any issues with the efficacy or safety data submitted in the application<\/strong>\n<\/p>\n<p>BASKING RIDGE, N.J. &amp; RAHWAY, N.J., June 26, 2024 \u2013 The U.S. Food and Drug Administration (FDA) has issued a<br \/>\n    Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of Daiichi<br \/>\n    Sankyo (TSE: 4568) and Merck\u2019s (known as MSD outside of the United States and Canada) (NYSE: MRK) patritumab<br \/>\n    deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small<br \/>\n    cell lung cancer (NSCLC) previously treated with two or more systemic therapies.<\/p>\n<p>&nbsp;<\/p>\n<p>The CRL results from findings pertaining to an inspection of a third-party manufacturing facility. The<br \/>\n    CRL did not identify any issues with the efficacy or safety data submitted.<\/p>\n<p>&nbsp;<\/p>\n<p>Patritumab deruxtecan is a specifically engineered potential first-in-class HER3 directed DXd antibody drug conjugate<br \/>\n    (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and Merck.&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>\u201cWe will work closely with the FDA and the third-party manufacturer to address the feedback as quickly as possible in<br \/>\n    order to bring the first HER3 directed medicine to patients with previously-treated EGFR-mutated non-small cell lung<br \/>\n    cancer,\u201d said Ken Takeshita, MD, Global Head, R&amp;D, Daiichi Sankyo. \u201cWe remain confident in the ability to<br \/>\n    develop this medicine to its full potential.\u201d<\/p>\n<p>&nbsp;<\/p>\n<p>\u201cPatients with previously treated EGFR-mutated non-small cell lung cancer often experience recurrence and have<br \/>\n    limited treatment options,\u201d said Marjorie Green, MD, Senior Vice President and Head<br \/>\n    of Oncology, Global Clinical Development, Merck Research Laboratories. &#8220;We are committed to working with Daiichi Sankyo and the FDA to prioritize making patritumab deruxtecan available to these patients in need.\u201d<\/p>\n<p>&nbsp;<\/p>\n<p>The BLA is based on the primary results from the&nbsp;<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04619004\">HERTHENA-Lung01<\/a>&nbsp;pivotal phase 2 trial that<br \/>\n    were&nbsp;<a href=\"https:\/\/daiichisankyo.us\/press-releases\/-\/article\/patritumab-deruxtecan-demonstrated-clinically-meaningful-and-durable-responses-in-patients-with-egfr-mutated-metastatic-non-small-cell-lung-cancer-in-\">presented<\/a>&nbsp;at<br \/>\n    the IASLC 2023 World Conference on Lung Cancer (#WCLC23) and simultaneously published in the<em>&nbsp;<\/em><a href=\"https:\/\/nam04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fascopubs.org%2Fdoi%2F10.1200%2FJCO.23.01476&amp;data=05%7C01%7Crlipson%40dsi.com%7Cfe94c68c81404e01a2e808dbaf02fada%7Cb0179487302644f7bcd625ed452138d0%7C0%7C0%7C638296199571590565%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=cBgywXDhf%2FVATcS8Of02LtiyH7S8JAnoJR7JeJ74fAk%3D&amp;reserved=0\"><em>Journal<br \/>\n            of Clinical Oncology<\/em><\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p>In HERTHENA-Lung01, patritumab deruxtecan was studied in 225 patients with EGFR-mutated locally advanced or<br \/>\n    metastatic NSCLC following disease progression with an EGFR TKI and platinum-based chemotherapy, which demonstrated<br \/>\n    an objective response rate (ORR) of 29.8% (95% CI: 23.9-36.2), including one complete response and 66 partial<br \/>\n    responses. The median duration of response (DoR) was 6.4 months (95% CI: 4.9-7.8).<\/p>\n<p>&nbsp;<\/p>\n<p>The safety profile of patritumab deruxtecan observed in HERTHENA-Lung01 was consistent with previous phase 1 clinical<br \/>\n    trials in NSCLC with a treatment discontinuation rate of 7.1% due to treatment-emergent adverse events (TEAEs).<br \/>\n    Grade 3 or higher TEAEs occurred in 64.9% of patients. The most common (\u22655%) grade 3 or higher TEAEs were<br \/>\n    thrombocytopenia (21%), neutropenia (19%), anemia (14%), leukopenia (10%), fatigue (6%), hypokalemia (5%) and<br \/>\n    asthenia (5%). Twelve patients (5.3%) had confirmed treatment-related interstitial lung disease (ILD) as determined<br \/>\n    by an independent adjudication committee. One grade 5 ILD event was observed.<\/p>\n<p><strong>&nbsp;<\/strong><\/p>\n<p><strong>About HERTHENA-Lung01 <\/strong><\/p>\n<p>HERTHENA-Lung01 is a global, multicenter, open-label, two-arm phase 2 trial evaluating the safety and efficacy of<br \/>\n    patritumab deruxtecan in patients with EGFR-mutated locally advanced or metastatic NSCLC following disease<br \/>\n    progression with an EGFR TKI and platinum-based chemotherapy. Patients were randomized 1:1 to receive 5.6 mg\/kg<br \/>\n    (n=225) or an uptitration regimen (n=50). The uptitration arm was discontinued as the dose of 5.6 mg\/kg of<br \/>\n    patritumab deruxtecan was selected following a risk-benefit analysis conducted from the <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03260491\">phase 1<\/a> trial assessing the doses in a similar patient<br \/>\n    population.<\/p>\n<p>&nbsp;<\/p>\n<p>The primary endpoint of HERTHENA-Lung01 was ORR as assessed by blinded independent central review (BICR). Secondary<br \/>\n    endpoints included DoR, progression-free survival, disease control rate, and time to response<br \/>\n    \u2013 all assessed by both BICR and investigator assessment \u2013 as well as investigator-assessed ORR, overall survival,<br \/>\n    safety and tolerability.<\/p>\n<p>&nbsp;<\/p>\n<p>HERTHENA-Lung01 enrolled patients in Asia, Europe, North America and Oceania. For more information about the trial,<br \/>\n    visit <a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04619004\">ClinicalTrials.gov<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>About EGFR-mutated non-small cell lung cancer <\/strong><\/p>\n<p>Approximately 226,000 lung cancer cases were diagnosed in the U.S. in 2022. Lung cancer is the third most common<br \/>\n    cancer and the leading cause of cancer-related deaths in the U.S. NSCLC accounts for approximately 81% of all lung<br \/>\n    cancers in the U.S., with 52% having distant spread at diagnosis. EGFR mutations occur in approximately 1 in 5<br \/>\n    patients with NSCLC in Western populations.<\/p>\n<p><strong>&nbsp;<\/strong><\/p>\n<p><strong>About HER3 <\/strong><\/p>\n<p>HER3 is a member of the EGFR family of receptor tyrosine kinases. It is estimated that about 83% of primary NSCLC<br \/>\n    tumors and 90% of advanced EGFR-mutated tumors express HER3 after prior EGFR TKI treatment. HER3 is associated with<br \/>\n    poor treatment outcomes, including shorter relapse-free survival and significantly reduced survival. There is<br \/>\n    currently no HER3 directed therapy approved for the treatment of any cancer.<\/p>\n<p><strong>&nbsp;<\/strong><\/p>\n<p><strong>About patritumab deruxtecan <\/strong><\/p>\n<p>Patritumab deruxtecan (HER3-DXd) is an investigational HER3 directed ADC. Designed using Daiichi Sankyo\u2019s proprietary<br \/>\n    DXd ADC Technology, patritumab deruxtecan is composed of a fully human anti-HER3 IgG1 monoclonal antibody attached<br \/>\n    to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable<br \/>\n    linkers.<\/p>\n<p>&nbsp;<\/p>\n<p>Patritumab deruxtecan was granted <a href=\"https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202112\/20211223_E1.pdf\">Breakthrough Therapy<br \/>\n        Designation<\/a> by the U.S. Food and Drug Administration in December 2021 for the treatment of patients with<br \/>\n    EGFR-mutated locally advanced or metastatic NSCLC with disease progression on or after treatment with a<br \/>\n    third-generation TKI and platinum-based therapies.<\/p>\n<p>&nbsp;<\/p>\n<p>Patritumab deruxtecan is currently being evaluated as both a monotherapy and in combination with other therapies in a<br \/>\n    global development program, which includes <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05338970\">HERTHENA-Lung02<\/a>, a phase 3 trial evaluating the<br \/>\n    efficacy and safety of patritumab deruxtecan versus platinum-based chemotherapy in patients with EGFR-mutated<br \/>\n    locally advanced or metastatic NSCLC following disease progression on or after treatment with a third-generation<br \/>\n    EGFR TKI; <a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04619004\">HERTHENA-Lung01<\/a>, a phase 2 trial in<br \/>\n    metastatic or locally advanced NSCLC with an activating EGFR mutation previously treated with at least one EGFR TKI<br \/>\n    and one platinum-based chemotherapy-containing regimen; <a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06172478\">HERTHENA-PanTumor01<\/a>, a <a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06172478\">phase 2 trial<\/a> in locally advanced or<br \/>\n    metastatic solid tumors, including melanoma, gastric and head and neck cancer, among other types of cancer,<br \/>\n    previously treated with at least one prior systemic therapy; a <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04676477\">phase 1 trial<\/a> in combination with osimertinib in<br \/>\n    EGFR-mutated locally advanced or metastatic NSCLC; and a <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03260491\">phase 1 trial<\/a> in previously treated patients with<br \/>\n    advanced NSCLC. A <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02980341\">phase 1\/2 trial<\/a> in HER3 expressing<br \/>\n    metastatic breast cancer also has been completed.<\/p>\n<p><strong>&nbsp;<\/strong><\/p>\n<p><strong>About the Daiichi Sankyo and <\/strong><strong>Merck collaboration<\/strong><\/p>\n<p>Daiichi Sankyo and Merck entered into a global collaboration in <a href=\"https:\/\/daiichisankyo.us\/press-releases\/-\/article\/daiichi-sankyo-and-merck-announce-global-development-and-commercialization-collaboration-for-three-daiichi-sankyo-dxd-adcs\">October<br \/>\n        2023<\/a> to jointly develop and commercialize patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd)<br \/>\n    and raludotatug deruxtecan (R-DXd), except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi<br \/>\n    Sankyo will be solely responsible for manufacturing and supply.&nbsp;&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><strong>About the DXd ADC portfolio of Daiichi Sankyo <\/strong><\/p>\n<p>The DXd ADC portfolio of Daiichi Sankyo currently consists of six ADCs in clinical development across multiple types<br \/>\n    of cancer. ENHERTU, a HER2 directed ADC, and datopotamab deruxtecan (Dato-DXd), a TROP2 directed ADC, are being<br \/>\n    jointly developed and commercialized globally with AstraZeneca. Patritumab deruxtecan (HER3-DXd), a HER3 directed<br \/>\n    ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC,<br \/>\n    are being jointly developed and commercialized globally with Merck. DS-3939, a TA-MUC1 directed ADC, is being<br \/>\n    developed by Daiichi Sankyo.<\/p>\n<p>&nbsp;<\/p>\n<p>Designed using Daiichi Sankyo\u2019s proprietary DXd ADC Technology to target and deliver a cytotoxic payload inside<br \/>\n    cancer cells that express a specific cell surface antigen, each ADC consists of a monoclonal antibody attached to a<br \/>\n    number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.\n<\/p>\n<p>&nbsp;<\/p>\n<p>Datopotamab deruxtecan, ifinatamab deruxtecan, patritumab deruxtecan, raludotatug deruxtecan and DS-3939 are<br \/>\n    investigational medicines that have not been approved for any indication in any country. Safety and efficacy have<br \/>\n    not been established.<\/p>\n<p><strong>&nbsp;<\/strong><\/p>\n<p><strong>About Daiichi Sankyo <\/strong><\/p>\n<p>Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that<br \/>\n    discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more<br \/>\n    than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new<br \/>\n    modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet<br \/>\n    medical needs. For more information, please visit <a href=\"http:\/\/www.daiichisankyo.com\">www.daiichisankyo.com<\/a>.\n<\/p>\n<p><strong>&nbsp;<\/strong><\/p>\n<p><strong>Merck\u2019s focus on cancer <\/strong><\/p>\n<p>Every day, we follow the science as we work to discover innovations that can help patients, no matter what stage of<br \/>\n    cancer they have. As a leading oncology company, we are pursuing research where scientific opportunity and medical<br \/>\n    need converge, underpinned by our diverse pipeline of more than 25 novel mechanisms. With one of the largest<br \/>\n    clinical development programs across more than 30 tumor types, we strive to advance breakthrough science that will<br \/>\n    shape the future of oncology. By addressing barriers to clinical trial participation, screening and treatment, we<br \/>\n    work with urgency to reduce disparities and help ensure patients have access to high-quality cancer care. Our<br \/>\n    unwavering commitment is what will bring us closer to our goal of bringing life to more patients with cancer. For<br \/>\n    more information, visit&nbsp;<a href=\"https:\/\/www.merck.com\/research\/oncology\/\">https:\/\/www.merck.com\/research\/oncology\/<\/a>.<\/p>\n<p><strong>&nbsp;<\/strong><\/p>\n<p><strong>About Merck <\/strong><\/p>\n<p>At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power<br \/>\n    of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to<br \/>\n    humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive<br \/>\n    biopharmaceutical company in the world \u2013 and today, we are at the forefront of research to deliver innovative health<br \/>\n    solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and<br \/>\n    inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for<br \/>\n    all people and communities. For more information, visit <a href=\"http:\/\/www.merck.com\">www.merck.com<\/a> and connect<br \/>\n    with us on <a href=\"https:\/\/twitter.com\/Merck\">X (formerly Twitter)<\/a>, <a href=\"https:\/\/www.facebook.com\/MerckInvents\">Facebook<\/a>, <a href=\"https:\/\/www.instagram.com\/merck\">Instagram<\/a>, <a href=\"https:\/\/www.youtube.com\/Merck\">YouTube<\/a> and <a href=\"https:\/\/www.linkedin.com\/company\/merck\">LinkedIn<\/a>.<\/p>\n<p><strong>&nbsp;<\/strong><\/p>\n<p><strong>Forward-Looking Statement of Merck &amp; Co., Inc., Rahway, N.J., USA<\/strong><\/p>\n<p>This news release of Merck &amp; Co., Inc., Rahway, N.J., USA (the \u201ccompany\u201d) includes \u201cforward-looking statements\u201d<br \/>\n    within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These<br \/>\n    statements are based upon the current beliefs and expectations of the company\u2019s management and are subject to<br \/>\n    significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the<br \/>\n    candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If<br \/>\n    underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially<br \/>\n    from those set forth in the forward-looking statements.<\/p>\n<p>&nbsp;<\/p>\n<p>Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic<br \/>\n    factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry<br \/>\n    regulation and health care legislation in the United States and internationally; global trends toward health care<br \/>\n    cost containment; technological advances, new products and patents attained by competitors; challenges inherent in<br \/>\n    new product development, including obtaining regulatory approval; the company\u2019s ability to accurately predict future<br \/>\n    market conditions; manufacturing difficulties or delays; financial instability of international economies and<br \/>\n    sovereign risk; dependence on the effectiveness of the company\u2019s patents and other protections for innovative<br \/>\n    products; and the exposure to litigation, including patent litigation, and\/or regulatory actions.<\/p>\n<p>&nbsp;<\/p>\n<p>The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new<br \/>\n    information, future events or otherwise. Additional factors that could cause results to differ materially from those<br \/>\n    described in the forward-looking statements can be found in the company\u2019s Annual Report on Form 10-K for the year<br \/>\n    ended December 31, 2023 and the company\u2019s other filings with the Securities and Exchange Commission (SEC) available<br \/>\n    at the SEC\u2019s Internet site (<a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=53871409&amp;newsitemid=20231214762284&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=c9e5a2afe154895b02fe7be8aae8c52f\">www.sec.gov<\/a>).\n<\/p>\n<p>&nbsp;<\/p>\n<table>\n<tbody>\n<tr>\n<td style=\"width: 110px;\">Media<br \/>Contacts:<\/td>\n<td style=\"width: 140.023px;\"><b>Merck<\/b><\/td>\n<td style=\"width: 99.9766px;\">Investor Contacts:<\/td>\n<td style=\"width: 45px;\"><b>Merck<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"width: 110px;\">&nbsp;<\/td>\n<td style=\"width: 140.023px;\">Julie Cunningham<\/p>\n<p>(617) 519-6264<br \/> <a href=\"mailto:julie.cunningham@merck.com\">julie.cunningham@merck.com<\/a><\/p>\n<\/td>\n<td style=\"width: 99.9766px;\">&nbsp;<\/td>\n<td style=\"width: 45px;\">\n<p>Peter Dannenbaum<br \/>(732) 594-1579<br \/> <a href=\"mailto:peter.dannenbaum@merck.com\">peter.dannenbaum@merck.com<\/a><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 110px;\">&nbsp;<\/td>\n<td style=\"width: 140.023px;\">\n<p>Nikki Lupinacci<br \/> (718) 644-0730 <a href=\"mailto:Nicole.lupinacci@merck.com\">Nicole.lupinacci@merck.com<\/a><\/p>\n<\/td>\n<td style=\"width: 99.9766px;\">&nbsp;<\/td>\n<td style=\"width: 45px;\">\n<p>Damini Chokshi<br \/> (732) 594-1577 <a href=\"mailto:Damini_chokshi@merck.com\">Damini_chokshi@merck.com<\/a><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 110px;\">&nbsp;<\/td>\n<td style=\"width: 140.023px;\">\n<p><strong>Daiichi Sankyo<br \/> Global\/US Media:<\/strong> Jennifer Brennan<br \/> <a href=\"mailto:jbrennan2@dsi.com\">jbrennan2@dsi.com<\/a><br \/> (908) 900-3183 (mobile)<\/p>\n<\/td>\n<td style=\"width: 99.9766px;\">&nbsp;<\/td>\n<td style=\"width: 45px;\">\n<p><strong>Daiichi Sankyo<\/strong><br \/> <a href=\"mailto:DaiichiSankyoIR@daiichisankyo.co.jp\">DaiichiSankyoIR@daiichisankyo.co.jp<\/a><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 110px;\">&nbsp;<\/td>\n<td style=\"width: 140.023px;\">\n<p><strong>Japan Media: <\/strong><a href=\"mailto:DS-PR@daiichisankyo.co.jp\">DS-PR@daiichisankyo.co.jp<\/a><\/p>\n<\/td>\n<td style=\"width: 99.9766px;\">&nbsp;<\/td>\n<td style=\"width: 45px;\">&nbsp;<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- DivTable.com --><\/p>\n<p><!-- \n\n<p>&nbsp;<\/p>\n\n\n\n\n<p><a href=\"#_ednref1\" name=\"_edn1\"><\/a>References:<\/p>\n\n\n\n\n<p><strong>i<\/strong> World Health Organization. International Agency for Research on Cancer. <a href=\"https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/840-united-states-of-america-fact-sheet.pdf\">U.S. Cancer Fact Sheet.<\/a> Accessed June 2024.<\/p>\n\n\n\n\n<p><strong>ii<\/strong> American Society of Clinical Oncology. <a href=\"https:\/\/www.cancer.net\/cancer-types\/lung-cancer-non-small-cell\/statistics#:~:text=NSCLC%20is%20the%20most%20common%20type%20of%20lung,United%20States%20will%20be%20diagnosed%20with%20lung%20cancer\">Lung Cancer \u2013 Non-Small Cell: Statistics<\/a>. Accessed June 2024.<\/p>\n\n\n\n\n<p><strong>iii<\/strong> SEER. <a href=\"https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=612&amp;data_type=1&amp;graph_type=4&amp;compareBy=sex&amp;chk_sex_1=1&amp;race=1&amp;age_range=1&amp;advopt_precision=1&amp;hdn_view=1&amp;advopt_show_apc=on&amp;advopt_display=2#resultsRegion1\">Adenocarcinoma of the Lung and Bronchus Stage Distribution of SEER Incidence Cases<\/a>. 2012-2021. Accessed June 2024.<\/p>\n\n\n\n\n<p><strong>iv<\/strong> Tan AC, et al. <a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.21.01626?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed\"><em>J Clin Oncol<\/em><\/a>. 2022;40(6):611-625.<\/p>\n\n\n\n\n<p><strong>v<\/strong> Mishra R, et al. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30057690\"><em>Onco Rev<\/em><\/a>. 2018; 12(355):45-62.<\/p>\n\n\n\n\n<p><strong>vi<\/strong> Scharpenseel H, et al. <a href=\"https:\/\/www.nature.com\/articles\/s41598-019-43678-6#Sec1\"><em>Scientific Reports<\/em>.<\/a> 2019; 9:7406.<\/p>\n\n\n\n\n<p><strong>vii<\/strong> Yonesaka K, et al. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34921025\/\"><em>Clin Cancer Res<\/em>.<\/a> 2022; 15:28(2):390-403.<\/p>\n\n\n\n\n<p><strong>viii<\/strong> Gandullo-S\u00e1nchez L et al.&nbsp;<a href=\"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-022-02515-x#citeas\"><em>J Exp Clin Cancer Res<\/em><\/a><em>.<\/em>&nbsp;2022; 41:310.<\/p>\n\n\n\n\n<p><strong>ix<\/strong> Yu H.A., et al. <a href=\"https:\/\/www.annalsofoncology.org\/article\/S0923-7534(24)00047-4\/fulltext\"><em>Annals of Oncology<\/em><\/a>. 2024; 35(5): P437-447.<\/p>\n\n\n\n<style><\/style>\n\n --><br class=\"t-last-br\"><\/p>\n<style><\/style>\n<style><\/style>\n","protected":false},"excerpt":{"rendered":"<p>The letter did not identify any issues with the efficacy or safety data submitted in the application BASKING RIDGE, N.J. &amp; RAHWAY, N.J., June 26, 2024 \u2013 The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of Daiichi Sankyo (TSE: 4568) and Merck\u2019s (known as MSD outside of the United States and Canada) (NYSE: MRK) patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies. The CRL results from findings pertaining to an inspection of a third-party manufacturing facility. The CRL did not identify any issues with the efficacy or safety data submitted. Patritumab deruxtecan is a specifically engineered potential first-in-class HER3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-3651540","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"The letter did not identify any issues with the efficacy or safety data submitted in the application BASKING RIDGE, N.J. &amp; RAHWAY, N.J., June 26, 2024 \u2013 The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of Daiichi Sankyo (TSE: 4568) and Merck\u2019s (known as MSD outside of the United States and Canada) (NYSE: MRK) patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies. The CRL results from findings pertaining to an inspection of a third-party manufacturing facility. The CRL did not identify any issues with the efficacy or safety data submitted. Patritumab deruxtecan is a specifically engineered potential first-in-class HER3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-31T17:58:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer\\\/\",\"name\":\"Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2024-06-26T23:15:00+00:00\",\"dateModified\":\"2025-12-31T17:58:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer\/","og_locale":"en_US","og_type":"article","og_title":"Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer - Merck.com","og_description":"The letter did not identify any issues with the efficacy or safety data submitted in the application BASKING RIDGE, N.J. &amp; RAHWAY, N.J., June 26, 2024 \u2013 The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of Daiichi Sankyo (TSE: 4568) and Merck\u2019s (known as MSD outside of the United States and Canada) (NYSE: MRK) patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies. The CRL results from findings pertaining to an inspection of a third-party manufacturing facility. The CRL did not identify any issues with the efficacy or safety data submitted. Patritumab deruxtecan is a specifically engineered potential first-in-class HER3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer\/","og_site_name":"Merck.com","article_modified_time":"2025-12-31T17:58:07+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer\/","name":"Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2024-06-26T23:15:00+00:00","dateModified":"2025-12-31T17:58:07+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"5b673066-0d8f-4bd5-b51b-b71ca1e7e844","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/2024\/06\/Merck-Joint-News-Release-06-26-24-Patritumab-Deruxtecan-BLA-Submission-Receives-Complete-Response-Letter-from-FDA-Due-to-Inspection-Findings-at-Third-Party-Manufacturer.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/3651540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":3,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/3651540\/revisions"}],"predecessor-version":[{"id":3678713,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/3651540\/revisions\/3678713"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=3651540"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=3651540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}